NRM Corporation Pty Ltd v Australian Competition and Consumer Commission

Link copied
Case Copied 81 min read

FEDERAL COURT OF AUSTRALIA

NRM Corporation Pty Ltd v Australian Competition and Consumer Commission [2016] FCAFC 98

Appeal from: Australian Competition and Consumer Commission v
ACN 117 372 915 Pty Limited (in liq) (formerly Advanced Medical Institute Pty Limited)
[2015] FCA 368
File number: VID 239 of 2015
Judges: FLICK, MURPHY AND GRIFFITHS JJ
Date of judgment: 21 July 2016
Catchwords:

CONSUMER PROTECTION – unfair contract – unconscionability – undesirability of providing a comprehensive definition – the vulnerability of the consumer 

PRACTICE AND PROCEDURE – findings of fact in respect to matters not pleaded – need for amendment – findings made in respect to matters canvassed and put in issue at hearing

PRACTICE AND PROCEDURE – alleged delay in publication of reasons for decision – delay of itself not a ground of appeal

PRACTICE AND PROCEDURE – need for caution before finding a witness has been untruthful – need to explain why evidence has been rejected

Legislation:

Competition and Consumer Act 2010 (Cth), Sch 2, ss 21, 24, 25, 250

Trade Practices Act1974 (Cth), ss 51AB, 51AC

Cases cited:

Australian Competition and Consumer Commission v ACN 099 814 749 Pty Ltd [2016] FCA 403

Australian Competition and Consumer Commission v ACN 117 372 915 Pty Limited (in liq) [2015] FCA 368

Australian Competition and Consumer Commission v ACN 117 372 915 Pty Ltd (in liq) [2015] FCA 1441

Australian Competition and Consumer Commission v Allphones Retail Pty Ltd (No 2) [2009] FCA 17, (2009) 253 ALR 324

Australian Competition and Consumer Commission v Chrisco Hampers Australia Ltd [2015] FCA 1204

Australian Competition and Consumer Commission v Clinica Internationale Pty Ltd (No 2) [2016] FCA 62

Australian Competition and Consumer Commission v Coles Supermarkets Australia Pty Ltd [2014] FCA 1405

Australian Competition and Consumer Commission v Dukemaster Pty Ltd [2009] FCA 682

Australian Competition and Consumer Commission v Lux Distributors Pty Ltd [2013] FCAFC 90

Australian Competition and Consumer Commission v Multimedia International Services Pty Ltd [2016] FCA 439

Australian Securities and Investments Commission v National Exchange Pty Ltd [2005] FCAFC 226, (2005) 148 FCR 132

Australian Competition and Consumer Commission v Origin Energy Electricity Ltd [2015] FCA 278

Director of Consumer Affairs (Vic) v Scully [2013] VSCA 292, (2013) 303 ALR 168

Expectation Pty Ltd v PRD Realty Pty Ltd [2004] FCAFC 189

JR Consulting & Drafting Pty Ltd v Cummings [2016] FCAFC 20, (2016) 329 ALR 625

Mbuzi v Griffith University [2014] FCA 1323, (2014) 146 ALD 543

MM Constructions (Aust) Pty Ltd v Port Stephens Council (No 7) [2012] NSWCA 417, (2012) 191 LGERA 292

Monie v Commonwealth of Australia [2005] NSWCA 25, (2005) 63 NSWLR 729

NAIS v Minister for Immigration and Multicultural and Indigenous Affairs [2005] HCA 77, (2005) 228 CLR 470

Paciocco v Australia and New Zealand Banking Group Ltd [2015] FCAFC 50, (2015) 236 FCR 199

PT Ltd v Spuds Surf Chatswood Pty Ltd [2013] NSWCA 446

Smith v New South Wales Bar Association (1992)…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read NRM Corporation Pty Ltd v Australian Competition and Consume... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2016] FCAFC 98
Decision Date

CaseChat Overview and Summary

The case of NRM Corporation Pty Ltd v Australian Competition and Consumer Commission involved a dispute over unfair contract terms and unconscionability under Australian consumer protection law. The respondents, NRM Corporation Pty Ltd and AMI Corporation Pty Ltd, appealed against findings made by the primary Judge in a decision that their business practices were unconscionable and that certain contract terms were unfair. The primary issues for the court were whether the primary Judge made findings outside the scope of the pleadings, whether there was an absence of clinical evidence as to the efficacy of the medications offered, and whether the findings regarding the remuneration of salespeople and the use of high-pressure sales techniques were supported by the evidence. The court had to consider whether the primary Judge erred in making certain findings of fact and if those findings led to a correct conclusion on the issue of unconscionability.

The court found that the primary Judge did not err in making findings outside the scope of the pleadings as the issues canvassed at the hearing were sufficiently broad to encompass the matters decided by the primary Judge. It was also determined that the primary Judge's findings regarding the lack of clinical evidence supporting the efficacy of the medications were supported by the evidence presented. The court emphasised the importance of viewing the findings in their full context rather than in isolation. Regarding the remuneration of salespeople and the use of high-pressure sales techniques, the court held that the findings were adequately supported by the evidence and were integral to the primary Judge's reasoning on unconscionability. The court was satisfied that the primary Judge's conclusions were properly drawn from the evidence and that there was no error in the findings that led to the ultimate conclusion of unconscionability.

The appeal was dismissed, and the appellants were ordered to pay the respondent's costs. The court's decision reinforced the importance of transparency in business practices and the need for businesses to avoid exploiting the vulnerability of consumers, particularly when it comes to health-related services and products.

Orders

Orders of the court

1. The appeal is dismissed.

2. The Appellants are to pay the costs of the Respondent.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Evidence

Evidence Before The Court

This Ground should be rejected. It mirrors the first underlying concern expressed by Senior Counsel for the Appellants. It was the Appellants who set out to prove the medical efficacy of the treatments they offered. No appellable error is exposed by the primary Judge making findings of fact as to “the appropriate pharmacological and medical treatment of premature ejaculation (PE) and erectile dysfunction (ED)”. The absence of clinical evidence – Ground 1(b) Ground 1(b) of the Further Amended Notice of Appeal refers to paras [343], [602], [741], [920] and [1003] of the reasons for decision of the primary Judge. The written outline of submissions filed by the Appellants was decidedly unhelpful. Those submissions did little more than contend that this Ground was outside the case as pleaded and “was against the evidence”. Confined to that submission, the Ground would inevitably fail. Each of the paragraphs relied upon by the Appellants was said to refer in one way or another to the absence of clinical evidence as to the efficacy of the Appellants’ medications. But the selection of these paragraphs for that purpose seems, with respect, to be somewhat indiscriminate. They seem to have been selected more by reference to a word-processor “word search” than by reference to selecting those specific paragraphs in which findings as to clinical efficacy have been made. Paragraph [741], for instance, is more directed to a finding as to the comparative cost of medications and treatment than to a finding of clinical efficacy. And para [920] is directed to those factors relied upon to reach a conclusion as to unconscionability rather than a finding in its own right as to clinical efficacy. Paragraph [920] thus builds upon the findings previously made. But such observations may be left to one side. Subject to those observations, each of the paragraphs relied upon by the Appellants was further expanded upon by the primary Judge and supported by evidence. It is, accordingly, a mistake to confine attention to the statements made in the paragraphs selected and in isolation from the remaining context. It is that context which gives content to the relevance of the findings made by the primary Judge and to the conclusions his Honour reaches. The context in which the findings relied upon by the Appellants, be it by reference to findings based upon evidence or by reference to findings forming part of the overall conclusions to be reached, can be summarised as follows: The written submission advanced on behalf of the Appellants as to an alleged absence of evidence is rejected. It was left to the Appellants’ written submissions in reply to those filed by the ACCC to more fully understand the case sought to be advanced on behalf of the Appellants. In reply the Appellants sought refuge once again in the submission as to findings being outside the pleadings. The submission in reply reduced to a submission that it “was not open to the trial judge to make a finding of unconscionability by resort to purported grounds of unconscionability which could have been, but which were not, pleaded”.

Decision

Reasons for decision

But, as is accepted in Ground 1(c), at least one relevant finding made by the primary Judge is that found in para [327]. That paragraph is found within Part 4.5.3.6.6 of the judgment, a Part which relevantly is expressed as follows: 4.5.3.6.6 CONCLUSION[321] The first reports of Dr Rowe and Dr Altman were written at a fairly high level of generality. At that level, it was possible for them to say that there was a theoretical pharmacological basis to support the efficacy of apomorphine and clomipramine delivered by the nasal route, the buccal route, or sublingually.[322] Both Dr Rowe and Dr Altman had previously had business relationships with AMI. Where it was possible to support the interests of the respondents in the course of their evidence, they were inclined to do so. It is not suggested that they compromised their professional integrity in the way they gave their evidence … …[327] In the end, Professor Pouton’s evidence that there is no scientific basis on which it can be concluded that the delivery of AMI and NRM medications through the nasal and buccal routes by nasal sprays, troches, or oral strips is effective should be accepted. A conclusion that the medications delivered in these ways were effective would be speculative.As is consistent with the manner in which the judgment of the primary Judge is otherwise drafted, these conclusions follow an analysis of the evidence of Drs Rowe and Altman and that of Professor Pouton and, more immediately, follow an analysis of:·Dr Rowe’s first report, in which he expressed his views (inter alia) as to the advantages of nasal and oral-strip delivery of medications (at paras [281] to [285]);·Dr Altman’s first report, in which he (inter alia) expressed his views as to the means of delivery adopted by AMI and NRM (at paras [286] to [289]); and·Professor Pouton’s report, in which he was (inter alia) critical of the therapeutic effect of alternative delivery systems (at paras [290] to [300]).The conclusions also contain an analysis of:·the further reports of Drs Rowe and Altman which had been given in response to the views expressed by Professor Pouton (at paras [301] to [311]); and·the cross-examination of Drs Rowe and Altman (at paras [312] to [320]). A review of the evidence as set forth by the primary Judge exposes no reason to question the findings made. A similar analysis can be undertaken in respect to the findings of the primary Judge at paras [602], [741], [920] and [1003]. To a very large extent these further findings can be traced back to the finding expressed at para [327] and to such further evidence to which his Honour expressly refers. Ground 1(c) is rejected.The off-label use of small doses & a question of pleadings – Grounds 1(d), (e), (f) & (g) Ground 1(d) of the Further Amended Notice of Appeal asserts that the primary Judge erred in “finding that there was no body of clinical experience of medical opinion based on the scientific foundation which supports the off-label use of small doses of apomorphine or clomipramine in nasal spray or oral strips for the treatment of ED or PE respectively…”.

Ratio Decidendi

Legal Principle Established

Ground 10 makes reference to para [905] of the reasons for decision of the primary Judge, which states as follows:[905] The failure to disclose the basis of the remuneration of salespeople was dishonest and exploitative, it was sharp practice and deceptive, particularly in the circumstances when men believed they were consulting a medical practice which characteristically make patient welfare a primary concern. It was an unfair tactic, which is a possible marker of unconscionable conduct referred to in s 51AB(2)(d) of the TPA, s 21(2)(d) of the ACL operating between 1 January 2011 and 1 January 2012, and s 22(1)(d) of the ACL in operation after 1 January 2012.This conclusion follows para [903], which states as follows:7.2.3 Remuneration of salespeople by commission[903] The salespeople were told by AMI and NRM in scripts and training materials not to disclose to patients that they were paid by commission. Payment by commission meant that the salespeople had an interest in selling higher priced programs. Had they disclosed that they were paid on commission, patients may have been alerted to the interest of the salespeople in selling higher priced programs. It may also have alerted patients to the fact that they were not consulting a traditional medical practice. The written submissions filed on behalf of the Appellants contend that the “implicit finding” in para [903], that patients were unaware that they were not consulting a “traditional medical practice”, was speculative. The submissions further state that none of the lay witnesses called by the ACCC gave evidence that they understood NRM to be “a traditional medical practice”. The difficulty confronted by this Ground is that it matters not what the expectations of the patients were when they consulted AMI or NRM. That which is of relevance is not their expectations but rather the fact that the salespeople failed to disclose the basis of their remuneration. There was no error in the finding of fact that the salespersons failed to disclose the basis of their remuneration. It was that failure to disclose which was central to the reasoning of the primary Judge at para [905] that patients were otherwise to assume that their welfare was the primary concern of the AMI and NRM practices. Ground 10 of the Further Amended Notice of Appeal is rejected. To the extent that Ground 10 seeks to challenge the findings of the primary Judge that the failure to disclose was “dishonest and exploitative”, and hence a step in the primary Judge’s reasoning to an ultimate finding of unconscionability, Ground 10 cannot be divorced from Grounds 11 and 12. High pressure sales techniques – Grounds 11 & 12 Grounds 11 and 12 of the Further Amended Notice of Appeal challenge the findings of the primary Judge in respect to the “high-pressure sales techniques” used by the salespeople. The findings made included the following: 7.2.2 High-pressure sales techniques[893] AMI and NRM salespeople were trained to use high-pressure sales techniques to sell the treatment programs. They were instructed in methods which were likely to frighten men into agreeing to the treatments offered by AMI and NRM.[894] The salespeople were trained to tell men that if they did not agree to treatment, they would suffer adverse medical consequences, including shrinkage of the penis and psychological impotence. There was no scientific basis established before the court for these claims. The salespeople were instructed to say that the treatment for ED would reduce the chance of heart attack or stroke. They were also instructed to inform patients that their partners may suffer from depression if they did not take the treatments. The threat of dire medical and social consequences placed pressure on men to accept the treatments.[895] The salespeople also told men that the medications would be effective not just to treat, but to cure their problems. This offered a further inducement to agree to treatment. And the men were reassured that if the treatment did not work they would be entitled to a refund.[896] This technique of selling was prone to rob men of independent judgement of the need for, and value of, the treatment, and induce them to enter into agreements which they would not otherwise have accepted if the pressure had not been applied.[897] The technique of frightening men by telling them of the dire adverse consequences of not agreeing to treatment and assuring them that the treatment was effective was part of the business system of AMI and NRM. It was formulated by management and imparted in an organised fashion through scripts and training sessions.The importance of these findings is that they form part of the reasoning later embraced by the primary Judge in reaching his conclusion as to unconscionability in para [939] of his reasons for decision. It is the finding at para [893] which is expressly the subject of challenge in Ground 11 of the Further Amended Notice of Appeal.